Multiboost - MCC plus pertussis booster in adolescents

INTERVENTION: Boostriv‐IPV, Combination dTaP3/IPV vaccine Meningitec, Meningococcal serogroup C conjugate vaccine Menitorix, Combined meningococcal serogroup C and Hib conjugate vaccine Menjugate, Meningococcal serogroup C conjugate vaccine NeisVac‐C, Meningococcal serogroup C conjugate vaccine Repevax, Combined dTaP5/IPV vaccine Follow Up Length: 1 month Study Entry : Single Randomisation only CONDITION: Topic: Medicines for Children Research Network, Primary Care Research Network for England; Subtopic: All Diagnoses, Not Assigned; Disease: All Diseases ; Infections and Infestations ; Vaccinations PRIMARY OUTCOME: Meningococcal serogroup C‐specific and pertussis‐specific immune response SECONDARY OUTCOME: 1. Safety and tolerability of each study combination of MCC and pertussis‐containing vaccine; 2. Tetanus, diphtheria, and (in appropriate study arms) Hib immune response INCLUSION CRITERIA: 1. Participant is willing and able to give written informed consent for participation. If aged below 16 years, parent/legal guardian gives consent while the participant gives written assent for participation in the study. ?2. Male or female aged 14 years (+0 day) to 17 years (+364 days) on the day of consent. ?3. Completed MCC and pertussis vaccination according to the UK (catch‐up and/or routine) schedule appropriate for the participant?s age